1-20 of 20
Ying Yuan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Timothy A. Lin, Zachary R. McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal Patel, Ramez Kouzy, Molly B. El Alam, Alexander D. Sherry, Sonal S. Noticewala, Clifton D. Fuller, Charles R. Thomas, Jr, Ryan Sun, J. Jack Lee, Ruitao Lin, Ying Yuan, Yu Shyr, Tomer Meirson, Ethan B. Ludmir
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (20): 4791–4799.
https://doi.org/10.1158/1078-0432.CCR-24-0566
Published: 15 October 2024
View article titled, Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation
Open the PDF for Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation in another window
Includes: Supplementary data
Journal Articles

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Ji Son, Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Alvarez Ballesteros, Mirella Nardo, Natalie Clark, R. Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M. Johnson, Amadeo B. Biter, Ying Yuan, Lauren P. Cobb, David M. Gershenson, Amir A. Jazaeri, Karen H. Lu, Pamela T. Soliman, Shannon N. Westin, Elizabeth D. Euscher, Barrett C. Lawson, Richard K. Yang, Funda Meric-Bernstam, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2986–2995.
https://doi.org/10.1158/1078-0432.CCR-23-2819
Published: 15 July 2024
View article titled, Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Open the PDF for Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)

Yixuan Zhao, Ying Yuan, Edward L. Korn, Boris Freidlin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 673–679.
https://doi.org/10.1158/1078-0432.CCR-23-2585
Published: 16 February 2024
View article titled, Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
Open the PDF for Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN) in another window
Includes: Supplementary data
Journal Articles

Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes

Peter F. Thall, Yong Zang, Andrew G. Chapple, Ying Yuan, Ruitao Lin, David Marin, Pavlos Msaouel
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4549–4554.
https://doi.org/10.1158/1078-0432.CCR-23-2222
Published: 14 November 2023
View article titled, Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes
Open the PDF for Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes in another window
Journal Articles

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

Feng Wang, Ming-Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Fu-Xiang Zhou, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng-Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si-Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4232–4239.
https://doi.org/10.1158/1078-0432.CCR-22-0655
Published: 03 October 2022
View article titled, A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Open the PDF for A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study) in another window
Includes: Supplementary data
Journal Articles

Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan, Diana Bell, Adel K. El-Naggar, Jason M. Johnson, William H. Morrison, David I. Rosenthal, Bonnie S. Glisson, Faye M. Johnson, Charles Lu, Frank E. Mott, Bita Esmaeli, Eduardo M. Diaz, Jr, Paul W. Gidley, Ryan P. Goepfert, Carol M. Lewis, Randal S. Weber, Jennifer A. Wargo, Sreyashi Basu, Fei Duan, Shalini S. Yadav, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1735.
https://doi.org/10.1158/1078-0432.CCR-22-0468
Published: 14 April 2022
View article titled, Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton, Aurora Blucher, Yong Fang, Christopher P. Vellano, Joseph R. Marszalek, Ningping Feng, XiaoYan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, Tae-Beom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T. Soliman, Michael Frumovitz, Katheleen M. Schmeler, Amir Jazaeri, Karen H. Lu, Rashmi Murthy, Larissa A. Meyer, Charlotte C. Sun, Anil K. Sood, Robert L. Coleman, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6354–6365.
https://doi.org/10.1158/1078-0432.CCR-21-1656
Published: 01 December 2021
View article titled, Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Open the PDF for Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck

Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, M. Laura Rubin, Ying Yuan, Diana Bell, Adel K. El-Naggar, Jason M. Johnson, William H. Morrison, David I. Rosenthal, Bonnie S. Glisson, Faye M. Johnson, Charles Lu, Frank E. Mott, Bita Esmaeli, Eduardo M. Diaz, Jr, Paul W. Gidley, Ryan P. Goepfert, Carol M. Lewis, Randal S. Weber, Jennifer A. Wargo, Sreyashi Basu, Fei Duan, Shalini S. Yadav, Padmanee Sharma, James P. Allison, Jeffrey N. Myers, Neil D. Gross
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4557–4565.
https://doi.org/10.1158/1078-0432.CCR-21-0585
Published: 15 August 2021
View article titled, Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Open the PDF for Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Jing Wu, Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung, Yu-Ting Su, Ying Pang, Guangyang Yu, Madison K. Butler, Tito R. Mendoza, Elizabeth Vera, Salman Ahmad, Christine Bryla, Matthew Lindsley, Ewa Grajkowska, Kelly Mentges, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Nicole Lollo, Christine Cordova, Orwa Aboud, Brett J. Theeler, Eric M. Burton, Marta Penas-Prado, Heather Leeper, Javier Gonzales, Terri S. Armstrong, Katherine R. Calvo, William D. Figg, Douglas B. Kuhns, John I. Gallin, Mark R. Gilbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3298–3306.
https://doi.org/10.1158/1078-0432.CCR-20-4730
Published: 15 June 2021
View article titled, Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Open the PDF for Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract PO049: Compartment-specific profiling for evaluation of disrupted signaling in early stage, low-grade endometrial cancer

Qian Zhang, Xiaoping Su, Joseph Celestino, Ying Yuan, Samuel C. Mok, Karen H. Lu, Melinda S. Yates
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3_Supplement): PO049.
https://doi.org/10.1158/1557-3265.ENDOMET20-PO049
Published: 01 February 2021
View article titled, Abstract PO049: Compartment-specific profiling for evaluation of disrupted signaling in early stage, low-grade endometrial cancer
Journal Articles

Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study

Pamela T. Soliman, Shannon N. Westin, David A. Iglesias, Bryan M. Fellman, Ying Yuan, Qian Zhang, Melinda S. Yates, Russell R. Broaddus, Brian M. Slomovitz, Karen H. Lu, Robert L. Coleman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 581–587.
https://doi.org/10.1158/1078-0432.CCR-19-0471
Published: 03 February 2020
View article titled, Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
Open the PDF for Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study in another window
Includes: Supplementary data
Journal Articles

Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas

Hong Jiang, Dong Ho Shin, Teresa T. Nguyen, Juan Fueyo, Xuejun Fan, Verlene Henry, Caroline C. Carrillo, Yanhua Yi, Marta M. Alonso, Tiara L. Collier, Ying Yuan, Frederick F. Lang, Candelaria Gomez-Manzano
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6801–6814.
https://doi.org/10.1158/1078-0432.CCR-19-0405
Published: 15 November 2019
View article titled, Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Open the PDF for Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas in another window
Includes: Supplementary data
Journal Articles

Accuracy, Safety, and Reliability of Novel Phase I Designs—Response

Heng Zhou, Ying Yuan, Lei Nie
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5483–5484.
https://doi.org/10.1158/1078-0432.CCR-18-2677
Published: 01 November 2018
View article titled, Accuracy, Safety, and Reliability of Novel Phase I Designs—Response
Open the PDF for Accuracy, Safety, and Reliability of Novel Phase I Designs—Response in another window
Journal Articles

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

Ying Yuan, Ruitao Lin, Daniel Li, Lei Nie, Katherine E. Warren
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 4921–4930.
https://doi.org/10.1158/1078-0432.CCR-18-0246
Published: 15 October 2018
View article titled, Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials
Open the PDF for Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials in another window
Includes: Supplementary data
Journal Articles

Accuracy, Safety, and Reliability of Novel Phase I Trial Designs

Heng Zhou, Ying Yuan, Lei Nie
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4357–4364.
https://doi.org/10.1158/1078-0432.CCR-18-0168
Published: 14 September 2018
View article titled, Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
Open the PDF for Accuracy, Safety, and Reliability of Novel Phase I Trial Designs in another window
Includes: Supplementary data
Journal Articles

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Fangrong Yan, Sumithra J. Mandrekar, Ying Yuan
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 3994–4003.
https://doi.org/10.1158/1078-0432.CCR-17-0220
Published: 01 August 2017
View article titled, Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials
Open the PDF for Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters

Janelle B. Pakish, Qian Zhang, Zhongyuan Chen, Han Liang, Gary B. Chisholm, Ying Yuan, Samuel C. Mok, Russell R. Broaddus, Karen H. Lu, Melinda S. Yates
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4473–4481.
https://doi.org/10.1158/1078-0432.CCR-16-2655
Published: 01 August 2017
View article titled, Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters
Open the PDF for Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters in another window
Includes: Supplementary data
Journal Articles

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials

Ying Yuan, Kenneth R. Hess, Susan G. Hilsenbeck, Mark R. Gilbert
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4291–4301.
https://doi.org/10.1158/1078-0432.CCR-16-0592
Published: 31 August 2016
View article titled, Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
Open the PDF for Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials in another window
Includes: Supplementary data
Journal Articles

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Hanguang Hu, Hang Zhang, Weiting Ge, Xiyong Liu, Sofia Loera, Peiguo Chu, Huarong Chen, Jiaping Peng, Lun Zhou, Shujing Yu, Ying Yuan, Suzhan Zhang, Lily Lai, Yun Yen, Shu Zheng
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5438–5448.
https://doi.org/10.1158/1078-0432.CCR-12-0124
Published: 30 September 2012
View article titled, <em>Secreted Protein Acidic and Rich in Cysteines-like 1</em> Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers
Open the PDF for <em>Secreted Protein Acidic and Rich in Cysteines-like 1</em> Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

Dimpy Koul, Jun Fu, Ruijun Shen, Tiffany A. LaFortune, Shuzhen Wang, Ningyi Tiao, Yong-Wan Kim, Juinn-Lin Liu, Deepti Ramnarian, Ying Yuan, Carlos Garcia-Echevrria, Sauveur-Michel Maira, W.K. Alfred Yung
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (1): 184–195.
https://doi.org/10.1158/1078-0432.CCR-11-1558
Published: 02 January 2012
View article titled, Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Open the PDF for Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells in another window
Includes: Supplementary data